Vitamins are the largest selling segment of global dietary supplement market registering a revenue of USD 37.64 billion in 2018. North America and Europe together account for 55.74 per cent of the global vitamin and mineral market share followed by the Asia-pacific region. According to estimates over 33 per cent of population in the United States of America and in many European countries like United Kingdom, Denmark, and Sweden regularly use multi vitamin mineral (MVM) preparations as dietary supplements. Studies assessing the prescribing behaviour of doctors in various parts of India reveal that vitamins constitute about 24-25 per cent of all prescribed drugs, however, the rationale behind this practice is not clear. MVM preparations are also readily available over the counter and are often consumed by patients and general public as health tonics. The reason for their sales possibly includes a belief that these are required for the well-being of an individual.

B-vitamins are a class of water-soluble vitamins that are commonly used as a dietary supplement. These are a diverse group of chemical substances comprising of thiamine (B1); riboflavin (B2); niacin (B3); pantothenic acid (B5); pyridoxine (B6); biotin (B7); folic acid (B9) and cyanocobalamin (B12) which are collectively referred to as ‘vitamin B complex’. These are essential for meeting the metabolic demands of the body as most of them serve as co-enzymes involved in various metabolic pathways (Table I). Many of these are also available as fixed dose combinations (FDCs) with other vitamins and minerals (MVM).

B-vitamins are used for the treatment of specific vitamin deficiency disorders such as beriberi (thiamine); pellagra (niacin) or certain non-nutritional disorders like Wernicke–Korsakoff syndrome (thiamine) and hyperlipidaemia (niacin). B-vitamins are also given prophylactically to prevent adverse effects of drug therapy, for example, those receiving isoniazid (300 mg or more) are given vitamin B6 (pyridoxine) in a dose of 10 mg daily to prevent peripheral neuropathy while those receiving cycloserine would require pyridoxine in a dose of 100-150 mg/day to reduce the incidence of its neurological adverse effects. However, there is so far no clear evidence that vitamin B complex is beneficial in the treatment of peripheral neuropathy from other causes such as diabetes mellitus and alcoholism. The routine use of B-vitamins may be indicated in some population groups. For example, folic acid is recommended for women of childbearing age and vitamin B-12 for adults of age above 50 yr. There is a strong evidence that a daily intake of at least 450 μg dietary folate equivalents in non-pregnant non-lactating women decreases the incidence of neural tube defects (NTDs) in newborns.

B-vitamins are often used in conditions not characterized with a vitamin B deficiency for which evidence for efficacy is lacking (Table II). Clinical studies and guidelines have consistently reported no clear benefits or possible harm of using B-vitamins or MVM supplements for decreasing morbidity and mortality due to major chronic diseases. For example, the use of B-vitamins like folic acid has been found harmful in those with high baseline homocysteine levels. Similarly, the use of MVM supplements containing beta carotene increases the risk for lung cancer and those with high-dose vitamin E increases overall mortality among users.

There is ample evidence to discourage the use of B-vitamins or MVM supplements in well-nourished adults. However, notwithstanding the above clinical situations, B-vitamins are often prescribed or self-administered by people regularly as nutrition supplements. It is even more perplexing how vitamin B complex, a FDC of B vitamins for which there is no evidence of efficacy at all is prescribed or used.

There are many FDCs of vitamin B complex available in the market. These contain different B
vitamins, sometimes other vitamins and minerals in variable quantities. The quantity of individual vitamin many a time does not coincide with their therapeutic or prophylactic doses. This aspect is not considered many times while prescribing. The analysis of the five most popular oral preparations of vitamin B complex available in the Indian market showed that half of the B-vitamins are present in their therapeutic doses while some are in their prophylactic dose along with other vitamins which do not have any recommended intake (Table III)\(^4\).

For example prescribing an MVM preparation containing folic acid, as shotgun therapy for treating vitamin B12 deficiency can not only obscure the possible diagnosis of pernicious anaemia but can also pose a risk of developing serious neurological complications\(^5\). The prophylactic dose of folic acid during pregnancy is 0.5 mg/day while its dose for the treatment of established anaemia is 5 mg/day but MVM preparations in the market have a variable composition of folic acid ranging from 0.5 to 5 mg\(^4\). A hypochromic anaemia which is not responsive to iron therapy may be benefited with pyridoxine (pyridoxine responsive hypochromic anaemia)\(^22\).

Pyridoxine is also a cofactor for enzyme dopa decarboxylase and its use in a Parkinson’s patient taking l-dopa may result in therapeutic failure\(^14\).

The Government of India through a gazette notification banned an FDC of vitamin B complex containing vitamin B1, B6, and B12 from January 1, 2001. A core group of experts appointed by the Supreme Court of India concluded that there was no rationality of this combination and it should be phased out from the market to prevent improper use. However, the pharmaceutical companies added other B-vitamins (vitamin B2; B3 and B5) to this combination, and this new recipe when marketed reported sales of over ₹161 crores in 2017\(^23\). It is considered to be among the top-selling FDC of vitamin B complex in the country. Introspection is needed as to how adding more drugs to a banned FDC will make it rational. Another dangerous trend that has emerged is combining drugs acting on different organ systems with vitamins. Few of such FDC’s (atorvastatin + vitamin B6/B9/B12 + vitamin D; ammonium citrate + vitamin B9/B12) also featured in the list of 344 FDC’s which were banned by the Government of India citing no therapeutic justification and potential risk to people\(^24\).

The economic consequences of irrational use of MVM as nutritional supplements can be realized

| Vitamins       | RDA\(^a\) | Deficiency cause                          | Deficiency syndrome and symptoms                  | Dose                        |
|----------------|----------|------------------------------------------|--------------------------------------------------|-----------------------------|
| Thiamine (B1)  | 1.2-1.7 mg/day | Dietary deficiency                        | Beri Beri, Wenick’s encephalopathy-Korsakoff psychosis | P: 2-10 mg/day T: 100 mg/day IV |
| Riboflavin (B2)| 1.4-2.1 mg/day | Dietary deficiency                        | Ariboflavinosis                                   | T: 2-20 mg/day               |
| Niacin (B3)    | 16-21 mg/day | Dietary deficiency (maize, jowar and bajra eaters) | Pellagra                                          | P: 20-50 mg/day T: 200-500 mg/day |
| Pantothenic acid (B5) | No recommendation | Dietary deficiency                        | Rare, fatigue, paresthesia, numbness, muscle cramp | T: 10-50 mg/day               |
| Pyridoxine (B6)| 2 mg/day | Dietary deficiency; drugs (isoniazid)     | Peripheral neuropathy, glositis, anorexia         | P: 2-5 mg/day T: 50-200 mg/day |
| Biotin (B7)    | No recommendation | Consuming raw egg whites                  | Rare, rashes, brittle hair, anemia, lethargy, anorexia, myalgia | No defined dose |
| Folic acid (B9)| 200 μg/day | Dietary deficiency                        | Megaloblastic anemia                              | P: 0.5 mg/day T: 1.5-5 mg/day |
| Cyanocobalamin (B12) | 1 µg/day | Dietary deficiency (vegetarian diet) Malabsorption (pernicious anemia) | Megaloblastic anemia Peripheral neuropathy         | P: 3-10 μg/day T: 100-1000 µg/week IV |

\(^a\)RDA refers to the amount of dietary nutrient required by a reference adult male (body weight 60 kg) to meet their physiological needs as per the dietary standards for the Indian population. P, prophylactic dose; T, therapeutic dose; RDA, recommended dietary allowance
from the fact that the global vitamin supplements market is expected to reach over USD 81 billion by the year 2025 with a significant rise in the vitamin-B product segment, soaring at a growth rate of 6.6 percent during 2019-2025. The Asia Pacific region, due to rapid urbanization and increased inclination towards preventive healthcare is expected to be the fastest emerging market for vitamin supplements.

### Table II. Current available evidence on using vitamin B for prophylaxis or management of diseases

| Review | Condition | Conclusion |
|--------|-----------|------------|
| Ang et al, 2008 | Peripheral neuropathy | Evidence is insufficient to determine whether vitamin B is beneficial or harmful for treating peripheral neuropathy |
| Raval et al, 2015 | Diabetic Kidney Disease (DKD) | No evidence to recommend the use of vitamin B therapy alone or in combination for delaying progression of DKD |
| Day, 2013 | Wernicke-korsakoff syndrome (WKS) | Evidence is insufficient to determine the dose, frequency, route or duration of thiamine treatment for prophylaxis against WKS or its treatment due to alcohol abuse |
| Rodriguez, 2001 | Alzheimer's disease | Sample size in studies was <50 and the reported results were inadequate to suggest regarding the efficacy of thiamine in Alzheimer’s diseases. |
| Schandelmaier, 2017 | Cardiovascular disease (CVD) | Evidence suggests that niacin does not reduce cardiovascular mortality from myocardial infarction or stroke but is associated with side effects |
| Malouf, 2003 | Cognitive impairment | No evidence for short-term benefit from vitamin B6 supplementation in mood or cognitive functions could be found especially among elderly and people with dementia |
| Salam, 2015 | Pregnancy and/or labour | Evidence is insufficient to determine the clinical benefits of vitamin B6 supplementation in pregnancy and/or labour. One clinical trial suggests protection against dental decay |
| De-Regil et al, 2015 | Neural tube defects (NTDs) and other congenital anomalies (including cleft palate) | Folic acid, prevents NTDs, but does not have a clear effect on other birth defects |
| Lassi et al, 2013 | Pregnancy outcomes (haematological and biochemical parameters during pregnancy) | No conclusive evidence to suggest that folic acid supplementation during pregnancy improves pregnancy outcomes like preterm birth and still birth/neonatal deaths |
| Shea et al, 2013 | Rheumatoid arthritis and its treatment side effects | Supplementation with folic or folinic acid has a protective effect on patients with rheumatoid arthritis during treatment with methotrexate (MTX) |
| Malouf and Areosa Sastre, 2003 | Cognitive impairment in demented and healthy elderly people | Insufficient evidence to determine the efficacy of vitamin B12 in improving the cognitive function among people with dementia and low serum B12 levels |

### Table III. Popular fixed dose combinations (FDCs) of vitamin B complex in Indian market

| Vitamins | Brand-A | Brand-B | Brand-C | Brand-D | Brand-E | Remarks |
|----------|---------|---------|---------|---------|---------|---------|
| Thiamine (B1) | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | Prophylactic dose |
| Riboflavin (B2) | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | Therapeutic dose |
| Niacin (B3) | 100 mg | 100 mg | 100 mg | 45 mg | 45 mg | Prophylactic dose |
| Pantothenic acid (B5) | 50 mg | 50 mg | 50 mg | 50 mg | 50 mg | Therapeutic dose |
| Pyridoxine (B6) | 3 mg | 3 mg | 3 mg | 3 mg | 3 mg | Prophylactic dose |
| Biotin (B7) | 100 µg | 100 µg | 100 µg | - | - | No recommendation |
| Folic acid (B9) | 1500 µg | 1500 µg | 1500 µg | - | - | Therapeutic dose (low) |
| Cyanocobalamin (B12) | 15 µg | 15 µg | 15 µg | 15 µg | 15 µg | Prophylactic dose |
| Other vitamins/minerals | vitamin-C | vitamin-C; zinc | - | - | - | |
Both China and India are projected to witness a growth rate of over 7.92 per cent in vitamin and mineral supplement market\(^1\). In countries like India where 70 per cent of healthcare expenses are met by out-of-pocket expenditure by patient and medicines account for over half of this expenditure, it is important to reduce indiscriminate use of multivitamin preparations, and the savings could be better spent elsewhere.

India is facing over-nutrition and obesity as serious emerging public health problems over an existing burden of under-nutrition. Like other medicines, vitamins must be prescribed for specific indications as per the scientific evidence and their indiscriminate use for health promotion or prevention of chronic diseases should be stopped. Evidence-based guidelines for the use of vitamin/mineral supplements must be developed by building consensus among experts from the fields of nutrition, pharmacology and clinicians across various specialties. These guidelines should be formulated considering the dietary needs of Indian population and must also clarify the role of nutritional supplements in individuals otherwise taking a regular diet. The formulation of such guidelines can not only check the indiscriminate use of MVM preparations but can also serve as a benchmark to ban irrational or harmful FDCs. There needs to be a stringent regulatory system in place to prevent marketing of FDCs which do not have a concrete scientific basis. The consumers and prescribers must also be educated as regards to the importance of balanced diet vis-a-vis nutritional supplements, which are often not needed for maintaining health but can cause harm and a wastage of economic resources. This holds true even more so for B-vitamins, a much-misused vitamin complex.

Financial support & sponsorship: None.

Conflicts of Interest: None.

Proteesh Rana\(^1,2,*\) and Vandana Roy\(^2,*\)

1Department of Pharmacology, Atal Bihari Vajpayee Institute of Medical Sciences & Dr Ram Manohar Lohia Hospital, Delhi 110 001 & 2Department of Pharmacology, Maulana Azad Medical College, University of Delhi, New Delhi 110 002, India

*For correspondence: roy.vandana@gmail.com

Received August 26, 2019

References

1. Dietary supplements market size analysis report by ingredient, by form, by application, by end user, by distribution channel and segment forecasts, 2019-2025. Available from: https://www.reportbuyer.com/product/5785377/dietary-supplements-market-size-analysis-report-by-ingredient-by-form-by-application-by-end-user-by-distribution-channel-and-segment-forecasts-2019-2025.html#free-sample, accessed on December 13, 2019.

2. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, et al. Dietary supplement use in the United States, 2003-2006. *J Nutr* 2011; 141: 261-6.

3. Kumari R, Idris MZ, Bhusan V, Khamna A, Agrawal M, Singh SK. Assessment of prescription pattern at the public health facilities of Lucknow district. *Indian J Pharmacol* 2008; 40: 243-7.

4. Indian Council of Medical Research. *Nutrient requirements and recommended dietary allowances for Indians*. A report of the Expert Group of the Indian Council of Medical Research. ICMR-NIN: Hyderabad, India; 2009.

5. Menon AS, Narula AS, Mathur AG. Multivitamins: Use or misuse? *Med J Armed Forces India* 2008; 64: 263-7.

6. Bhargava M, Bhargava A. Pyridoxine for patients suffering from drug-susceptible tuberculosis in India. *Public Health Action* 2018; 8: 97.

7. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MVC, Tan JJ, et al. Vitamin B for treating peripheral neuropathy. *Cochrane Database Syst Rev* 2008; 3: CD004573.

8. De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solón P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev* 2015; 12: CD007950.

9. Raval AD, Thakker D, Rangoonwala AN, Gor D, Walia R. Vitamin B and its derivatives for diabetic kidney disease. *Cochrane Database Syst Rev* 2015; 1: CD009403.

10. Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and treatment of Wernicke-Korsakoff syndrome in people who abuse alcohol. *Cochrane Database Syst Rev* 2013; 7: CD004393.

11. Rodriguez-Martín JL, Qizilbash N, López-Arrieta JM. Thiamine for Alzheimer’s disease. *Cochrane Database Syst Rev* 2001; 2: CD001498.

12. Schandelmaier S, Briel M, Sacilotto R, Olu KK, Arpagus A, Hemkens LG, et al. Niacin for primary and secondary prevention of cardiovascular events. *Cochrane Database Syst Rev* 2017; 6: CD009744.

13. Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. *Cochrane Database Syst Rev* 2003; 4: CD004393.

*Present Address: Department of Pharmacology, University College of Medical Sciences, Delhi 110 095, India*
14. Salam RA, Zuberi NF, Bhutta ZA. Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. *Cochrane Database Syst Rev* 2015; 6 : CD000179.

15. Lassi ZS, Salam RA, Haider BA, Bhutta ZA. Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes. *Cochrane Database Syst Rev* 2013; 3 : CD006896.

16. Shea B, Swiden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, *et al.* Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev* 2013; 5 : CD000951.

17. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. *Cochrane Database Syst Rev* 2003; 3 : CD004326.

18. Guallar E, Stranges S, Mulrow C, Appel LJ, Miller ER 3rd. Enough is enough: Stop wasting money on vitamin and mineral supplements. *Ann Intern Med* 2013; 159 : 850-1.

19. Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. *Am J Cardiol* 2010; 106 : 517-27.

20. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2013; 159 : 824-34.

21. CIMS. Available from: https://www.mims.com/india, accessed on March 7, 2019.

22. Clayton PT. B6-responsive disorders: A model of vitamin dependency. *J Inherit Metab Dis* 2006; 29 : 317-26.

23. Ghangurde A. E-Merck Reformulates Neurobion to Tackle Ban on Fixed Dose Combinations. Indian Express Newspapers LTD; 2000. Available from: http://expressindia.indianexpress.com/fe/daily/20000621/fco21041.html, accessed on March 6, 2019.

24. National Health Portal India. Complete list of 344 drugs banned by the Ministry of Health & Family Welfare. Available from: https://www.nhp.gov.in/Complete-list-of-344-drugs-banned-by-the-Ministry-of-Health-Family-welfare_pg, accessed on March 6, 2019.

25. Persistence Market Research. Vitamins supplements market.. Available from: https://www.perspectivesmarketresearch.com/ market-research/vitamins-supplements-market.asp, accessed on August 10, 2019.